Results 161 to 170 of about 430,211 (318)

Updated COVID‐19 Vaccines and Health Outcomes in Patients With Autoimmune Rheumatic Conditions

open access: yesArthritis &Rheumatology, EarlyView.
Objective We aimed to assess the association between COVID‐19 vaccination status and COVID‐19‐related hospital admissions, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and death in people with autoimmune rheumatic conditions. Methods We conducted a retrospective cohort study using National Clinical Cohort Collaborative
Lesley E. Jackson   +127 more
wiley   +1 more source

CASTOR1 Regulates Humoral Immune Responses and Contributes to the Pathogenesis of Systemic Lupus Erythematosus

open access: yesArthritis &Rheumatology, EarlyView.
Objective CASTOR1 senses arginine and regulates mammalian target of rapamycin complex 1 (mTORC1), a central metabolic signaling molecule. This study aimed to elucidate the roles of CASTOR1 in humoral immune responses. Methods We analyzed human B cell transcriptomes from healthy controls and patients with systemic lupus erythematosus (SLE) via ...
Takeshi Kusuda   +5 more
wiley   +1 more source

Optimizing Efficacy to Safety Ratio of Glucocorticoids in Rheumatoid Arthritis Models by Leveraging Peroxisome Proliferator–Activated Nuclear Receptor‐α Agonism

open access: yesArthritis &Rheumatology, EarlyView.
Objective Glucocorticoids remain essential therapies for immune and inflammatory diseases such as rheumatoid arthritis (RA) but are notorious for their metabolic side effects. Given the anti‐inflammatory and metabolically favorable actions of peroxisome proliferator–activated nuclear receptor (PPAR) agonists, we investigated whether PPARα agonism could
Lisa L. Koorneef   +17 more
wiley   +1 more source

Higher risk of Long COVID among patients with autoimmune rheumatic diseases and immunomodulatory therapy: a retrospective cohort analysis of national US data.

open access: yesArthritis &Rheumatology, Accepted Article.
Background Little is known about the prevalence of and factors associated with Long COVID in patients with autoimmune rheumatic diseases (AIRDs). Methods We conducted a retrospective cohort study using data from the National Clinical Cohort Collaborative (N3C).
Namrata Singh   +11 more
wiley   +1 more source

General best practices Part 1-2020 [PDF]

open access: yes
CDC is offering a series of weekly one-hour web-on-demand videos that will provide an overview of vaccination principles, general best practices, immunization strategies, and specific information about vaccine-preventable diseases and the vaccines that ...

core  

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar   +6 more
wiley   +1 more source

Ferritin as a Nanoparticle Scaffold for Plant‐Produced Next‐Generation Subunit Vaccines

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Protein nanoparticles offer an innovative approach to next‐generation subunit vaccine development by displaying antigenic sequences on the nanoparticle surface. Compared to traditional subunit vaccines, protein nanoparticle vaccines often show improved interaction with the immune system due to their particulate size and repetitive epitope ...
Jordan T. VanderBurgt   +3 more
wiley   +1 more source

GMMA as adjuvant and carrier for mucosal delivery of group A streptococcus glycoconjugate vaccine. [PDF]

open access: yesHum Vaccin Immunother
Ozanne J   +10 more
europepmc   +1 more source

Purification of Disassembled Capsid Protein by Hydroxyapatite Chromatography Enhances Virus‐Like Particle Recovery

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Virus‐like particles (VLPs) are a promising modality with extensive applications in prophylactic and therapeutic vaccine design. Human Papillomavirus (HPV) vaccines are one such example where VLP vaccine applications have led to the successful reduction in HPV‐associated diseases, such as cervical cancer.
Nicholas Samuelson   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy